Replies to post #253449 on Avid Bioservices Inc (CDMO)

[cjgaddy]

Right, def. 2 Arms in SUNRISE (50% get Bavi+Doce, 50% get DoceOnly – All Weekly). Maybe he got confused with the upcoming AZN-Collab. Bavi+Durva/NSCLC N=198 Ph2 trial, which will have 3 arms (A./DurvaOnlyBiWK, B./BaviWEEKLY+DurvaBiWK, C.BaviBiWK+DurvaBiWK)...
PS: I'm personally very happy that in the new AZN/Bavi+Druva trial, 67% will get the benefit of Bavi, rather than 50% in Sunrise.

= = = = = = = = = = = =
Q. Phase II Bavi+durvalumab(anti-PD-L1 MEDI4736), 2ndLine NSCLC(squa+nonsq.), randomized, open-lab, n=198, AZN Collab.)
Protocol: http://www.clinicaltrials.gov/ct2/show/NCT02673814 <=added 2-2-16
...3 Arms: A./DurvaOnlyBiWK, B./BaviWEEKLY+DurvaBiWK, C.BaviBiWK+DurvaBiWK
...Est. Enrollment: 198, Study Start: Feb. 2016, Est.Prim.Comp: Apr.2017 (Final data coll. for prim.outcome), Est.StudyComp: Apr.2018

= = = = = = = = = = =
A. Phase III Bavi+Doce vs. 2nd-Line NSCLC "SUNRISE" (randomized, double-blind, placebo-ctl'd, n=582)
USA Protocol: http://www.clinicaltrials.gov/ct2/show/NCT01999673 <=chgd. to "Active, Not Recruiting." 2-2-16
Geo/Map view of Worldwide Ph3 SUNRISE Sites: http://www.medbravo.org/study?study=NCT01999673
...161 sites a/o 7-9-15 (USA/39 Aus/9 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/8 Spain/16 Taiwan/10 Ukraine/6) - Growth: http://tinyurl.com/qbemrr2